Clofarabine
- Generic Name
- Clofarabine
- Brand Names
- Clolar, Evoltra
- Drug Type
- Small Molecule
- Chemical Formula
- C10H11ClFN5O3
- CAS Number
- 123318-82-1
- Unique Ingredient Identifier
- 762RDY0Y2H
- Background
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...
- Indication
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
- Associated Conditions
- Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
- Associated Therapies
- -
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00462787
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 2000
- Registration Number
- NCT00454480
- Locations
- 🇬🇧
Queen's Hospital, Burton-upon-Trent, England, United Kingdom
🇬🇧Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
🇬🇧Hereford Hospitals, Hereford, United Kingdom
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT00423514
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
2 Arm Study of Clofarabine IV in MDS Patients
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00422032
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00416351
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00412243
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
HSCT for High Risk Inherited Inborn Errors
- Conditions
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 38
- Registration Number
- NCT00383448
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
- Conditions
- Interventions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 116
- Registration Number
- NCT00373529
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 74
- Registration Number
- NCT00372619
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Yale University
- Target Recruit Count
- 16
- Registration Number
- NCT00338494
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.